AR activates YAP/TAZ differentially in prostate cancer

Life Sci Alliance. 2023 Jun 29;6(9):e202201620. doi: 10.26508/lsa.202201620. Print 2023 Sep.

Abstract

The Hippo signalling pathway is a master regulator of cell growth, proliferation, and cancer. The transcriptional coregulators of the Hippo pathway, YAP and TAZ, are central in various cancers. However, how YAP and TAZ get activated in most types of cancers is not well understood. Here, we show that androgens activate YAP/TAZ via the androgen receptor (AR) in prostate cancer (PCa), and that this activation is differential. AR regulates YAP translation while inducing transcription of the TAZ encoding gene, WWTR1 Furthermore, we show that AR-mediated YAP/TAZ activation is regulated by the RhoA GTPases transcriptional mediator, serum response factor (SRF). Importantly, in prostate cancer patients, SRF expression positively correlates with TAZ and the YAP/TAZ target genes CYR61 and CTGF We demonstrate that YAP/TAZ are not essential for sustaining AR activity, however, targeting YAP/TAZ or SRF sensitize PCa cells to AR inhibition in anchorage-independent growth conditions. Our findings dissect the cellular roles of YAP, TAZ, and SRF in prostate cancer cells. Our data emphasize the interplay between these transcriptional regulators and their roles in prostate tumorigenesis and highlight how these insights might be exploited therapeutically.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Androgens
  • Carcinogenesis
  • Humans
  • Male
  • Prostate
  • Prostatic Neoplasms* / genetics
  • Receptors, Androgen* / genetics
  • Transcriptional Coactivator with PDZ-Binding Motif Proteins / metabolism

Substances

  • Androgens
  • Receptors, Androgen
  • AR protein, human
  • YAP1 protein, human
  • Transcriptional Coactivator with PDZ-Binding Motif Proteins